Galderma Reports Promising Long-Term Data for Prurigo Nodularis Treatment

Galderma has shared new interim results from the OLYMPIA long-term extension trial of Nemluvio, a monoclonal antibody for moderate-to-severe prurigo nodularis (PN). The data show sustained symptom relief over two years, with over 90% of patients reporting a four-point or greater reduction in itch and 80% showing significant healing of skin lesions.

The trial, involving 508 participants from earlier Phase II and III studies, also showed high rates of skin nodule clearance based on the Investigator’s Global Assessment. Nemluvio, which targets the IL-31 receptor alpha, is the first biologic approved for both PN and atopic dermatitis (AD), with four-week dosing intervals.

Approved by the FDA in 2024 for PN in adults and later for AD in patients 12+, it is marketed as Mitchga in Japan. Galderma holds global rights (except Japan) after acquiring them from Chugai in 2016.

23-06-2025